1. Home
  2. SCYX vs DSWL Comparison

SCYX vs DSWL Comparison

Compare SCYX & DSWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • DSWL
  • Stock Information
  • Founded
  • SCYX 1999
  • DSWL 1987
  • Country
  • SCYX United States
  • DSWL Macau
  • Employees
  • SCYX N/A
  • DSWL N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • DSWL Plastic Products
  • Sector
  • SCYX Health Care
  • DSWL Industrials
  • Exchange
  • SCYX Nasdaq
  • DSWL Nasdaq
  • Market Cap
  • SCYX 36.8M
  • DSWL 37.8M
  • IPO Year
  • SCYX 2014
  • DSWL 1995
  • Fundamental
  • Price
  • SCYX $0.74
  • DSWL $2.47
  • Analyst Decision
  • SCYX
  • DSWL
  • Analyst Count
  • SCYX 0
  • DSWL 0
  • Target Price
  • SCYX N/A
  • DSWL N/A
  • AVG Volume (30 Days)
  • SCYX 170.9K
  • DSWL 21.6K
  • Earning Date
  • SCYX 08-07-2025
  • DSWL 06-18-2025
  • Dividend Yield
  • SCYX N/A
  • DSWL 8.10%
  • EPS Growth
  • SCYX N/A
  • DSWL 45.62
  • EPS
  • SCYX N/A
  • DSWL 0.70
  • Revenue
  • SCYX $2,630,000.00
  • DSWL $67,610,000.00
  • Revenue This Year
  • SCYX $463.61
  • DSWL N/A
  • Revenue Next Year
  • SCYX $310.80
  • DSWL N/A
  • P/E Ratio
  • SCYX N/A
  • DSWL $3.51
  • Revenue Growth
  • SCYX N/A
  • DSWL N/A
  • 52 Week Low
  • SCYX $0.72
  • DSWL $1.93
  • 52 Week High
  • SCYX $2.29
  • DSWL $2.74
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 37.94
  • DSWL 58.38
  • Support Level
  • SCYX $0.72
  • DSWL $2.26
  • Resistance Level
  • SCYX $0.85
  • DSWL $2.48
  • Average True Range (ATR)
  • SCYX 0.05
  • DSWL 0.06
  • MACD
  • SCYX -0.01
  • DSWL 0.01
  • Stochastic Oscillator
  • SCYX 9.61
  • DSWL 73.21

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About DSWL Deswell Industries Inc.

Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.

Share on Social Networks: